Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.

ABSTRACT:

Background and aim

Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the current gold standard treatment for muscle-invasive urothelial bladder cancer (MIBC). Nonetheless, some MIBC patients showed limited pathological response after NAC. Herein, we used whole-exome sequencing (WES) to identify genetic mutations in MIBC that can predict NAC response.

Methods

Forty MIBC patients were enrolled in this study, in which 33 were successfully examined by WES and Sanger sequencing in the discovery cohort (n=13) and the validation cohort (n=20), respectively. ANNOVAR software was used to identify the potential mutations based on the data of WES. In addition, tumor-specific somatic mutations including single nucleotide variants and indels were called with

SUBMITTER: Yang Z 

PROVIDER: S-EPMC8259609 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature